Ellevest Inc’s Protagonist Therapeutics PTGX Stock Holding History

Ellevest Inc’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6	Closed	–	–	1604
2021 Q3	$0	Buy	+6	New	+$256	﹤0.01%	1537

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Ellevest Inc's PTGX Position: Q4 2021 in Review

Ellevest Inc sold out of Protagonist Therapeutics (PTGX) in Q4 2021, closing a stake of 6 shares.

Ellevest Inc first reported a position in PTGX in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 149 funds tracked by Wall St. Rank hold PTGX as of Q4 2021.

Ellevest Inc reported no remaining Protagonist Therapeutics position as of Q4 2021 after selling out during the quarter.
Ellevest Inc sold 6 Protagonist Therapeutics shares in Q4 2021.
Ellevest Inc first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 1 quarter.
Ellevest Inc's Protagonist Therapeutics position peaked at $0 in Q3 2021.
149 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2021.

Based on Ellevest Inc's 13F filing for Q4 2021, filed 24 Jan 2022.